Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients

International Journal of Infectious Diseases

Volumn 12, Issue 1, 2008, Pages 51-56

  Kuniholm, Mark H ^a   Mark, Jennifer ^a   Aladashvili, Malvina ^b   Shubladze, N ^c   Khechinashvili, G ^c   Tsertsvadze, Tengiz ^b   del Rio, Carlos ^d   Nelson, Kenrad E ^a,e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b AIDS and Clinical Immunology Research Center   (Georgia)

^c National Center of Tuberculosis and Lung Diseases   (Georgia)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Georgia; Hepatitis B; Hepatitis C; Hepatotoxicity; HIV; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TRANSFUSION; COMORBIDITY; EPIDEMIC; FEMALE; GEORGIA (REPUBLIC); HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRISON; QUESTIONNAIRE; RISK FACTOR; SCREENING TEST; SEROLOGY; SEXUAL BEHAVIOR; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALGORITHMS; COHORT STUDIES; FEMALE; GEORGIA (REPUBLIC); HEALTH SURVEYS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PRISONERS; RISK FACTORS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULOSIS;

EID: 37349004789     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.04.015     Document Type: Article

References (36)

1. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 (1999) 677-686
2. Dye C. Global epidemiology of tuberculosis. Lancet 367 (2006) 938-940
3. Baltussen R., Floyd K., and Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331 (2005) 1364
4. Raviglione M.C., and Uplekar M.W. WHO's new Stop TB Strategy. Lancet 367 (2006) 952-955
5. Schechter M., Zajdenverg R., Falco G., Barnes G.L., Faulhaber J.C., Coberly J.S., et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 173 (2006) 922-926
6. Kunimoto D., Warman A., Beckon A., Doering D., and Melenka L. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis 36 (2003) e158-e161
7. van Hest R., Baars H., Kik S., van Gerven P., Trompenaars M., Kalisvaart N., et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis 39 (2004) 488-496
8. Forget E.J., and Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 5 (2006) 231-249
9. Younossian A.B., Rochat T., Ketterer J.P., Wacker J., and Janssens J.P. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 26 (2005) 462-464
10. Fountain F.F., Tolley E., Chrisman C.R., and Self T.H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128 (2005) 116-123
11. Lobato M.N., Reves R.R., Jasmer R.M., Grabau J.C., Bock N.N., and Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 127 (2005) 1296-1303
12. Sharma S.K., Balamurugan A., Saha P.K., Pandey R.M., and Mehra N.K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166 (2002) 916-919
13. Pande J.N., Singh S.P., Khilnani G.C., Khilnani S., and Tandon R.K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51 (1996) 132-136
14. Fernandez-Villar A., Sopena B., Vazquez R., Ulloa F., Fluiters E., Mosteiro M., et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 36 (2003) 293-298
15. Sadaphal P., Astemborski J., Graham N.M., Sheely L., Bonds M., Madison A., et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 33 (2001) 1687-1691
16. Ungo J.R., Jones D., Ashkin D., Hollender E.S., Bernstein D., Albanese A.P., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157 (1998) 1871-1876
17. Pan L., Jia Z.S., Chen L., Fu E.Q., and Li G.Y. Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol 11 (2005) 2518-2521
18. Agal S., Baijal R., Pramanik S., Patel N., Gupte P., Kamani P., et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 20 (2005) 1745-1752
19. Tost J.R., Vidal R., Cayla J., Diaz-Cabanela D., Jimenez A., and Broquetas J.M. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 9 (2005) 534-540
20. Gordin F.M., Cohn D.L., Matts J.P., Chaisson R.E., and O'Brien R.J. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?. Clin Infect Dis 39 (2004) 561-565
21. Gulbay B.E., Gurkan O.U., Yildiz O.A., Onen Z.P., Erkekol F.O., Baccioglu A., et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 10 (2006) 1834-1842
22. Aziz H., Shubair M., Debari V.A., Ismail M., and Khan M.A. Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection. Curr Med Res Opin 22 (2006) 217-221
23. Lee B.H., Koh W.J., Choi M.S., Suh G.Y., Chung M.P., Kim H., et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 127 (2005) 1304-1311
24. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293 (2005) 2767-2775
25. Richards D.C., Mikiashvili T., Parris J.J., Kourbatova E.V., Wilson J.C., Shubladze N., et al. High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia. Int J Tuberc Lung Dis 10 (2006) 396-401
26. Weinstock D.M., Hahn O., Wittkamp M., Sepkowitz K.A., Khechinashvili G., and Blumberg H.M. Risk for tuberculosis infection among internally displaced persons in the Republic of Georgia. Int J Tuberc Lung Dis 5 (2001) 164-169
27. Aerts A., Habouzit M., Mschiladze L., Malakmadze N., Sadradze N., Menteshashvili O., et al. Pulmonary tuberculosis in prisons of the ex-USSR state of Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int J Tuberc Lung Dis 4 (2000) 1104-1110
28. Tkeshelashvili-Kessler A., del Rio C., Nelson K., and Tsertsvadze T. The emerging HIV/AIDS epidemic in Georgia. Int J STD AIDS 16 (2005) 61-67
29. Butsashvili M., Tsertsvadze T., McNutt L.A., Kamkamidze G., Gvetadze R., and Badridze N. Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors. Eur J Epidemiol 17 (2001) 693-695
30. Zaller N., Nelson K.E., Aladashvili M., Badridze N., del Rio C., and Tsertsvadze T. Risk factors for hepatitis C virus infection among blood donors in Georgia. Eur J Epidemiol 19 (2004) 547-553
31. Stvilia K., Tsertsvadze T., Sharvadze L., Aladashvili M., del Rio C., Kuniholm M.H., et al. Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia. J Urban Health 83 (2006) 289-298
32. World Health Organization. Global TB database. Georgia; 2005.
33. Pardini M., Iona E., Varaine F., Karakozian H., Arzumanian H., Brunori L., et al. Mycobacterium tuberculosis drug resistance, Abkhazia. Emerg Infect Dis 11 (2005) 501-503
34. Zalesky R., Abdullajev F., Khechinashvili G., Safarian M., Madaras T., Grzemska M., et al. Tuberculosis control in the Caucasus: successes and constraints in DOTS implementation. Int J Tuberc Lung Dis 3 (1999) 394-401
35. Fry R.S., Khoshnood K., Vdovichenko E., Granskaya J., Sazhin V., Shpakovskaya L., et al. Barriers to completion of tuberculosis treatment among prisoners and former prisoners in St. Petersburg, Russia. Int J Tuberc Lung Dis 9 (2005) 1027-1033
36. Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 44 (2006) S132-S139